644 Shares in GlaxoSmithKline plc (NYSE:GSK) Acquired by Savior LLC

Share on StockTwits

Savior LLC purchased a new position in shares of GlaxoSmithKline plc (NYSE:GSK) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 644 shares of the pharmaceutical company’s stock, valued at approximately $30,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Hall Laurie J Trustee grew its position in GlaxoSmithKline by 15.7% during the 3rd quarter. Hall Laurie J Trustee now owns 1,842 shares of the pharmaceutical company’s stock worth $79,000 after acquiring an additional 250 shares during the last quarter. NTV Asset Management LLC grew its position in GlaxoSmithKline by 1.7% during the 3rd quarter. NTV Asset Management LLC now owns 15,287 shares of the pharmaceutical company’s stock worth $652,000 after acquiring an additional 250 shares during the last quarter. MUFG Americas Holdings Corp grew its position in GlaxoSmithKline by 0.7% during the 3rd quarter. MUFG Americas Holdings Corp now owns 34,118 shares of the pharmaceutical company’s stock worth $1,456,000 after acquiring an additional 253 shares during the last quarter. Gofen & Glossberg LLC IL grew its position in GlaxoSmithKline by 0.9% during the 3rd quarter. Gofen & Glossberg LLC IL now owns 27,908 shares of the pharmaceutical company’s stock worth $1,191,000 after acquiring an additional 260 shares during the last quarter. Finally, Traverso Chambers Private Wealth Management LLC grew its position in GlaxoSmithKline by 2.6% during the 3rd quarter. Traverso Chambers Private Wealth Management LLC now owns 11,124 shares of the pharmaceutical company’s stock worth $475,000 after acquiring an additional 279 shares during the last quarter. Institutional investors and hedge funds own 11.27% of the company’s stock.

A number of equities research analysts have recently weighed in on GSK shares. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating in a research report on Wednesday, November 27th. Cantor Fitzgerald upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. ValuEngine upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, December 20th. New Street Research raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Wednesday, October 16th. Finally, Svb Leerink began coverage on shares of GlaxoSmithKline in a report on Monday, December 2nd. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of $47.33.

GSK stock opened at $47.82 on Friday. GlaxoSmithKline plc has a 1 year low of $38.16 and a 1 year high of $48.22. The company has a market cap of $119.20 billion, a P/E ratio of 20.44, a PEG ratio of 3.16 and a beta of 0.68. The firm has a 50-day moving average of $46.79 and a 200 day moving average of $43.41. The company has a debt-to-equity ratio of 1.38, a current ratio of 0.82 and a quick ratio of 0.56.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. The business had revenue of $11.57 billion during the quarter, compared to analyst estimates of $11.34 billion. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. On average, equities research analysts expect that GlaxoSmithKline plc will post 3.3 earnings per share for the current fiscal year.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Dividend Reinvestment Plan (DRIP)

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.